Evidence map›Paper›PMID 35337274›Full record

Trial reportBMC gastroenterology2022

Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis.

Na Ryung Choi, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jihye Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Na Ryung ChoiDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Ju Yeon KimDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Ji Hoon HongDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Moon Haeng HurDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Heejin ChoDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Min Kyung ParkDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Jihye KimDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Yun Bin LeeDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Eun Ju ChoDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Jeong-Hoon LeeDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Su Jong YuDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Jung-Hwan YoonDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Yoon Jun KimDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea. yoonjun@snu.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimIn a randomized controlled trial, lenvatinib was non-inferior to sorafenib in overall survival (OS) of patients with unresectable hepatocellular carcinoma (uHCC). This study aimed to compare the effects of sorafenib and lenvatinib as first-line systemic therapy against uHCC with real-world data in chronic hepatitis B patients.

methodsThis retrospective single-center study involved 132 patients with HBV-related uHCC. Propensity score matching (PSM) was used to balance the baseline characteristics, including age, sex, serum alpha-fetoprotein levels, Child-Pugh class, tumor size, and tumor stage. The primary endpoint was overall survival (OS), and the secondary endpoints included progression-free survival (PFS), time to progression (TTP), and tumor response.

resultsAfter PSM, the final analysis included 44 patients treated with lenvatinib and 88 with sorafenib. The OS (7.0 vs 9.2 months, p = 0.070) and PFS (4.6 vs 2.4 months, p = 0.134) were comparable between the two drugs. Multivariable analysis showed that lenvatinib and sorafenib were not independent prognostic factors of OS (adjusted hazard ratio = 1.41, 95% confidence interval = 0.96-2.08, p = 0.077) after adjustment for baseline alpha-fetoprotein levels, total bilirubin levels, alanine aminotransferase level, performance status, tumor stage, and tumor size. However, the lenvatinib group had a significantly prolonged TTP (5.2 vs 2.5 months, p = 0.018) and a higher objective response rate (18.2% vs 4.5%, p = 0.020) and disease control rate (77.3% vs 47.7%, p = 0.001) than the sorafenib group.

conclusionsOur study demonstrated that lenvatinib had a comparable OS and PFS but longer TTP and better tumor response compared to sorafenib in patients with HBV-related uHCC.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsHepatitis B virusHumansPhenylurea CompoundsPropensity ScoreQuinolinesRetrospective StudiesSorafenibTreatment OutcomeAntineoplastic AgentslenvatinibPhenylurea CompoundsQuinolinesSorafenibCarcinomaChronicHepatitis BHepatocellularLenvatinibSorafenib

Identifiers

PMID35337274
PMCPMC8951695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.